Research shows 30% fewer prostate cancer deaths with PSA screening

PSA-screening cuts deaths from prostate cancer by 30%. This is based on research data from 20,000 men monitored for more than two decades. The PSA level initially measured in these men proved highly significant as a predictor of future cancer risk.

This research is important because it shows the long-term effects of an organized screening program.

The main purpose of this research was to enhance understanding of the implications of screening, and of the possible design of a future screening program for prostate cancer.

The study was unique in many ways, and to date, has the longest follow-up period of all screening studies on prostate cancer worldwide.

The Randomized Population-Based Prostate Cancer Screening Trial initially was comprised of a total of 20,000 men aged 50-64. 10,000 were randomly selected for a screening group and offered PSA testing (screening) every two years and cell sampling if elevated PSA levels were found. The remaining 10,000 were assigned to the control group and not offered PSA sampling in the study.

After 22 years of follow-up, approximately 300 men had died of prostate cancer. The risk was 30 percent lower for men who had undergone screening in the program. Men at the highest risk of dying from prostate cancer were those whose screening started after age 60; men who were diagnosed after leaving the study (aged about 70 and over); and those who were invited, but did not participate at all.

The study also included outcomes for men who participated in the screening program and left the trial without prostate cancer being detected. Among the men who were monitored for nine years after their screening ended, 200 cancer cases altogether were found. Of these men, 21 later died from the disease.

PSA levels on the first screening occasion proved to have a major bearing on future cancer outcomes. They may therefore be used for risk estimation. The results also showed that in men with voiding dysfunction — difficulty in emptying the bladder — the risk of prostate cancer was lower than in symptom-free men in the study.

Posted in Uncategorized.

Leave a Reply

Your email address will not be published.